The pharmacodiagnostic test is designed to identify patients more likely to benefit from Bristol-Myers’ investigational drug candidates.
Dakos CEO Lars Holmkvist said the partnership agreements simply underpin the company’s mission to deliver the highest standards and accurate diagnoses — ultimately to the benefit of patients.
